AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Robert F. Kennedy Jr. stated desire to ban drug commercials from TV seems unlikely to become reality, according to ...

Bioconjugation Market Bioconjugation Market Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Bioconjugation Market by Product ...

U.S. stocks indexes are drifting higher on Wall Street on the final day of another record-setting year. The S&P 500 was up ...

INR:7252. picvook tv Pfizer and Eli Lilly are ahead of AbbVie and are closely following the new battlefield of JAK inhibitors. Is this the place? New tumor immunothera ...

INR:3880. england vs pakistan live score Vitamin C and hyperthermia combined with effective treatment for refractory lung ...

This week, the department of pharmaceuticals (DoP) said the Indian arm of US firm AbbVie violated the newly amended Uniform Code for Pharmaceutical Marketing Practices. What did AbbVie do ...

Pharma department has reprimanded AbbVie Healthcare for sending 30 doctors to Paris and Monaco, spending over Rs 1.9 crore, violating uniform travel and hospitality guidelines. The National ...

Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures upadacitinib.

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

This discount is shown at checkout, if applicable. AbbVie is slated to buy oral peptide developer Nimble Therapeutics for $200 million, with the potential for a milestone payment. Nimble was spun ...